Transgene

Immunotherapy to fight cancer and infectious diseases

Home page

Site Map

Clinical Trials

	Corporate Overview History Products People

Executive Management Board Members Scientific Advisory Board Qualified Pharmacist Locations

	Products TG 4001/R3484 TG 4010 TG 1042 TG 4040 MyoDys®

	Research Technologies

	Facility Process Development Quality Control Contract Manufacturing Organization

	Strategy Key Partners

	Stock Quotes Key Facts Financial Information Statutory Declarations Conferences Calendar Analysts Coverage Investor Relations Contact

	Press Releases Management Presentations Publications

Company Profile - Product Pipeline - - Manufacturing - - - Investor Relations - News

Company Profile

Transgene is a biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products… more »

Corporate presentation
Annual Report 2006
Reference document 2007

Product Pipeline

TG 4001/R3484 (MVA-HPV-IL2) :	Phase II completed
TG 4010 (MVA-MUC1-IL2) :	Phase IIb
TG 1042 (Ad-IFNγ) :	Phase II
TG 4040 (MVA-HCV) :	Phase I
Myodys	Preclinical

Production

Since 1995, Transgene operates its own multi-use, multi-product manufacturing…
more »

News

Press Releases

June 23, 2008
Transgene appoints three Directors to its Board... more »

June 2, 2008
Transgene's therapeutic vaccine TG4010 ... more » (POSTER - PDF)(MEETING - PDF)

May 19, 2008
Transgene announces promising Phase I preliminary results ... more »

April 16, 2008
Transgene: cash position of € 105.8 million as of March 31, 2008 ... more »

Stock Quotes

Date : 07.05.2008 (delayed)

Euronext Paris Share
Last:	12.16(c) €
Volume:	30 112
Change:	-2.33%

-ANNUAL GENERAL MEETING - JUNE 9, 2008 -

- 2008 CONFERENCES -

Locations

Job Opportunities